细胞因子拮抗剂和免疫检查点抑制剂相关的真菌感染风险。
Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors.
机构信息
Department of Microbiology, The University of Hong Kong, Hong Kong.
State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong.
出版信息
Exp Biol Med (Maywood). 2020 Jul;245(13):1104-1114. doi: 10.1177/1535370220939862. Epub 2020 Jul 8.
Abstract
The risk of opportunistic infections due to fungi is relatively less well addressed in patients receiving biologic agents, compared with other opportunistic bacterial and viral infections. There is a lack of consensus guideline on the screening, prophylaxis, and management of fungal infection in patients anticipated to receive or actively receiving biologic therapy. In addition, invasive mycosis in immunocompromised patients is associated with high mortality and morbidity. This review highlighted the risk of fungal infection in patients receiving cytokine antagonists and immune checkpoint inhibitors, two big categories of biologic agents that are widely used in the treatment of various autoimmune and malignant conditions, often in combination with other immunomodulatory or immunosuppressive agents but also as standalone therapy. The adverse outcomes of opportunistic fungal infection in these patients can be reduced by heightened awareness, active case finding, and prompt treatment.
摘要
与其他机会性细菌和病毒感染相比，接受生物制剂治疗的患者，其真菌感染的机会相对较少得到解决。对于预计或正在接受生物治疗的患者，真菌感染的筛查、预防和管理缺乏共识指南。此外，免疫功能低下患者的侵袭性真菌感染与高死亡率和发病率相关。本综述强调了接受细胞因子拮抗剂和免疫检查点抑制剂治疗的患者发生真菌感染的风险，这两种生物制剂广泛用于治疗各种自身免疫和恶性疾病，通常与其他免疫调节或免疫抑制药物联合使用，但也可作为单一疗法。提高认识、主动发现病例和及时治疗可以降低这些患者发生机会性真菌感染的不良后果。
相似文献
1
Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors.细胞因子拮抗剂和免疫检查点抑制剂相关的真菌感染风险。
Exp Biol Med (Maywood). 2020 Jul;245(13):1104-1114. doi: 10.1177/1535370220939862. Epub 2020 Jul 8.
2
Tumor necrosis factor inhibition and invasive fungal infections.肿瘤坏死因子抑制与侵袭性真菌感染。
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S208-12. doi: 10.1086/430000.
3
Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies.治疗用单克隆抗体和其他免疫调节疗法后的真菌感染。
Rev Iberoam Micol. 2020 Jan-Mar;37(1):5-16. doi: 10.1016/j.riam.2019.09.001. Epub 2019 Dec 14.
4
Glucocorticoids and invasive fungal infections.糖皮质激素与侵袭性真菌感染。
Lancet. 2003 Nov 29;362(9398):1828-38. doi: 10.1016/S0140-6736(03)14904-5.
5
Risk of infection associated with new therapies for lymphoproliferative syndromes.与淋巴增生性综合征相关的新疗法的感染风险。
Med Clin (Barc). 2020 Feb 14;154(3):101-107. doi: 10.1016/j.medcli.2019.07.026. Epub 2019 Nov 23.
6
Eradicating, retaining, balancing, swarming, shuttling and dumping: a myriad of tasks for neutrophils during fungal infection.消除、保留、平衡、群集、穿梭和倾倒：中性粒细胞在真菌感染过程中执行的众多任务。
Curr Opin Microbiol. 2020 Dec;58:106-115. doi: 10.1016/j.mib.2020.09.011. Epub 2020 Oct 19.
7
Fungal Infections Potentiated by Biologics.生物制剂引发的真菌感染。
Infect Dis Clin North Am. 2020 Jun;34(2):389-411. doi: 10.1016/j.idc.2020.02.010. Epub 2020 Apr 23.
8
Host immune reactivity and antifungal chemotherapy: the power of being together.宿主免疫反应与抗真菌化疗：协同的力量。
J Chemother. 2001 Aug;13(4):347-53. doi: 10.1179/joc.2001.13.4.347.
9
Infectious Complications of Immune Checkpoint Inhibitors.免疫检查点抑制剂的感染并发症。
Infect Dis Clin North Am. 2020 Jun;34(2):235-243. doi: 10.1016/j.idc.2020.02.004. Epub 2020 Apr 23.
10
The impact of the host on fungal infections.宿主对真菌感染的影响。
Am J Med. 2012 Jan;125(1 Suppl):S39-51. doi: 10.1016/j.amjmed.2011.10.010.
引用本文的文献
1
Immunometabolic Interactions in Obesity: Implications for Therapeutic Strategies.肥胖中的免疫代谢相互作用：对治疗策略的启示。
Biomedicines. 2025 Jun 10;13(6):1429. doi: 10.3390/biomedicines13061429.
2
Deletion of core septin gene in results in fungicidal activity of caspofungin.核心septin基因的缺失导致卡泊芬净的杀真菌活性。
bioRxiv. 2025 Feb 25:2025.02.25.640155. doi: 10.1101/2025.02.25.640155.
3
Lethal Disseminated Mucorales Infection With Positive Blood Cultures With Purpura Fulminans Complicating Hemophagocytic Lymphohistiocytosis After Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞治疗后发生噬血细胞性淋巴组织细胞增生症并伴有暴发性紫癜、血培养阳性的致死性播散性毛霉目感染
Open Forum Infect Dis. 2024 Oct 29;11(11):ofae647. doi: 10.1093/ofid/ofae647. eCollection 2024 Nov.
4
Overview of the Current Challenges in Pulmonary Coccidioidomycosis.肺球孢子菌病当前挑战概述
J Fungi (Basel). 2024 Oct 18;10(10):724. doi: 10.3390/jof10100724.
5
Editorial: Invasive fungal diseases: pathogen detection and diagnosis development.社论：侵袭性真菌病：病原体检测与诊断进展
Front Cell Infect Microbiol. 2024 Sep 17;14:1473409. doi: 10.3389/fcimb.2024.1473409. eCollection 2024.
6
Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.镰刀菌属、枝顶孢属和繁茂枝孢菌：为世界卫生组织真菌病原体优先排序提供信息的系统综述。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myad128.
7
Musculoskeletal Coccidioidomycosis in the Setting of Adalimumab: A Case Report.阿达木单抗治疗背景下的肌肉骨骼球孢子菌病：一例报告
Cureus. 2024 Mar 17;16(3):e56321. doi: 10.7759/cureus.56321. eCollection 2024 Mar.
8
Immune Checkpoint Inhibitors and Infection: What Is the Interplay?免疫检查点抑制剂与感染：它们之间有什么相互作用？
In Vivo. 2023 Nov-Dec;37(6):2409-2420. doi: 10.21873/invivo.13346.
9
Rhino-Orbital Cerebral Mucormycosis in a Patient With Diabetic Ketoacidosis: A Case Report and Literature Review.一名糖尿病酮症酸中毒患者的鼻眶脑毛霉菌病：病例报告及文献综述
Front Neurol. 2022 May 4;13:815902. doi: 10.3389/fneur.2022.815902. eCollection 2022.
10
Precision Therapy for Invasive Fungal Diseases.侵袭性真菌病的精准治疗
J Fungi (Basel). 2021 Dec 27;8(1):18. doi: 10.3390/jof8010018.
本文引用的文献
1
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.免疫检查点抑制剂相关感染的诊断和管理建议。
Thorac Cancer. 2020 Mar;11(3):805-809. doi: 10.1111/1759-7714.13313. Epub 2020 Jan 22.
2
Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis.一名因检查点抑制剂诱导的肝炎而接受免疫抑制剂治疗的癌症患者发生坏死性软组织侵袭性曲霉病。
J Infect. 2020 Feb;80(2):232-254. doi: 10.1016/j.jinf.2019.10.022. Epub 2019 Nov 6.
3
Checkpoint Inhibition and Infectious Diseases: A Good Thing?免疫检查点抑制剂与感染性疾病：利乎？弊乎？
Trends Mol Med. 2019 Dec;25(12):1080-1093. doi: 10.1016/j.molmed.2019.08.004. Epub 2019 Sep 4.
4
Blockade Of PD-1 Attenuated Postsepsis Aspergillosis Via The Activation of IFN-γ and The Dampening of IL-10.PD-1 阻断通过激活 IFN-γ 和抑制 IL-10 减轻脓毒症后曲霉菌病。
Shock. 2020 Apr;53(4):514-524. doi: 10.1097/SHK.0000000000001392.
5
Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.治疗银屑病的选择性 IL-23p19 抑制剂的安全性。
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1676-1684. doi: 10.1111/jdv.15653. Epub 2019 Jun 27.
6
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗的肺癌患者中传染病的新关注点。
Respir Med. 2019 Jan;146:66-70. doi: 10.1016/j.rmed.2018.11.021. Epub 2018 Dec 13.
7
Tildrakizumab: A Review of Phase II and III Clinical Trials.替度鲁单抗：II 期和 III 期临床试验综述。
Ann Pharmacother. 2019 Apr;53(4):413-418. doi: 10.1177/1060028018809522. Epub 2018 Oct 20.
8
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.靶向细胞因子家族在炎症性疾病和癌症中的最新见解。
Nat Rev Immunol. 2018 Dec;18(12):773-789. doi: 10.1038/s41577-018-0066-7.
9
Biology and regulation of IL-2: from molecular mechanisms to human therapy.IL-2 的生物学和调控：从分子机制到人体治疗。
Nat Rev Immunol. 2018 Oct;18(10):648-659. doi: 10.1038/s41577-018-0046-y.
10
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.古塞库单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照、2 期研究。
Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.
Zotero 插件